The overall ratings of nine biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Kindred Biosciences, Inc. (KIN) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). In Portfolio Grader’s specific subcategories of Equity and Cash Flow, KIN also gets F’s. To get an in-depth look at KIN, get Portfolio Grader’s complete analysis of KIN stock.
Trius Therapeutics, Inc.’s (TSRX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
The rating of Vical Incorporated (VICL) declines this week from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.
Tenax Therapeutics, Inc. (TENX) is having a tough week. The company’s rating falls from a D to an F. The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The trailing PE Ratio for the stock is 107.30. For more information, get Portfolio Grader’s complete analysis of TENX stock.
This week, Oncothyreon (ONTY) drops from a C to a D rating. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at ONTY, get Portfolio Grader’s complete analysis of ONTY stock.
Seattle Genetics, Inc.’s (SGEN) rating weakens this week, dropping to an F versus last week’s D. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The stock gets F’s in Earnings Revisions and Equity. As of Feb. 17, 2015, 16.2% of outstanding Seattle Genetics, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
The rating of Inovio Pharmaceuticals, Inc. (INO) slips from a C to a D. Inovio Pharmaceuticals engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The stock gets F’s in Equity, Cash Flow and Sales Growth. As of Feb. 17, 2015, 19.2% of outstanding Inovio Pharmaceuticals, Inc. shares were held short. Shares of the stock have been exchanging at an usually rapid pace, twice the rate of the week prior. To get an in-depth look at INO, get Portfolio Grader’s complete analysis of INO stock.
This week, Ligand Pharmaceuticals Incorporated (LGND) drops from a C to a D rating. Ligand Pharmaceuticals develops drugs which regulate hormone activated intracellular receptors. The stock also rates an F in Earnings Revisions. As of Feb. 17, 2015, 23.9% of outstanding Ligand Pharmaceuticals Incorporated shares were held short. The stock has a trailing PE Ratio of 99.80. For more information, get Portfolio Grader’s complete analysis of LGND stock.
Slipping from a C to a D rating, Cara Therapeutics Inc (CARA) takes a hit this week. The stock also gets an F in Equity. To get an in-depth look at CARA, get Portfolio Grader’s complete analysis of CARA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
